These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 38953994

  • 1. Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment.
    Cheng CC, Chang J, Ho AS, Sie ZL, Peng CL, Wang CL, Dev K, Chang CC.
    Cancer Immunol Immunother; 2024 Jul 02; 73(9):175. PubMed ID: 38953994
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W, Zhou X, Zhai M, Li W, Ran Y, Sun Y, Du J, Zhao W, Xing L, Qi Y, Gao Y.
    Sci China Life Sci; 2021 Apr 02; 64(4):548-562. PubMed ID: 32737851
    [Abstract] [Full Text] [Related]

  • 5. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10.
    Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, He XL, Chen X, Chen X, Zhang B, Kai G, Zhang X, Li T, Huang M, Lu JJ.
    Pharmacol Res; 2023 Dec 02; 198():106988. PubMed ID: 37984507
    [Abstract] [Full Text] [Related]

  • 6. Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.
    Guo J, Xiao Y, Iyer R, Lu X, Lake M, Ladror U, Harlan J, Samanta T, Tomlinson M, Bukofzer G, Donawho C, Shoemaker A, Huang TH.
    PLoS One; 2019 Dec 02; 14(8):e0219829. PubMed ID: 31393905
    [Abstract] [Full Text] [Related]

  • 7. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM, Hicks KC, Ozawa Y, Schlom J, Gameiro SR.
    J Immunother Cancer; 2020 Apr 02; 8(1):. PubMed ID: 32303618
    [Abstract] [Full Text] [Related]

  • 8. Near-infrared photoimmunotherapy targeting PD-L1: Improved efficacy by preconditioning the tumor microenvironment.
    Inagaki FF, Kano M, Furusawa A, Kato T, Okada R, Fukushima H, Takao S, Okuyama S, Choyke PL, Kobayashi H.
    Cancer Sci; 2024 Jul 02; 115(7):2396-2409. PubMed ID: 38671582
    [Abstract] [Full Text] [Related]

  • 9. Targeting the TRIM14/USP14 Axis Enhances Immunotherapy Efficacy by Inducing Autophagic Degradation of PD-L1.
    Liu D, Li M, Zhao Z, Zhou L, Zhi F, Guo Z, Cui J.
    Cancer Res; 2024 Sep 04; 84(17):2806-2819. PubMed ID: 38924473
    [Abstract] [Full Text] [Related]

  • 10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, Li J, Wang J, Shi W, Wang L, Zheng Y, Sun Y.
    Theranostics; 2021 Sep 04; 11(7):3392-3416. PubMed ID: 33537094
    [Abstract] [Full Text] [Related]

  • 11. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
    Li L, Yang L, Cheng S, Fan Z, Shen Z, Xue W, Zheng Y, Li F, Wang D, Zhang K, Lian J, Wang D, Zhu Z, Zhao J, Zhang Y.
    Mol Cancer; 2019 Jun 20; 18(1):108. PubMed ID: 31221150
    [Abstract] [Full Text] [Related]

  • 12. Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.
    He N, Huang H, Wu S, Ji W, Tai Y, Gao R, Liu Y, Liu Y, Chen L, Zhu D, Zheng X, Jiang J.
    Cancer Sci; 2024 Jul 20; 115(7):2196-2208. PubMed ID: 38655660
    [Abstract] [Full Text] [Related]

  • 13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM, Khan PP, Wang H, Tsai WB, Qiao Y, Yu B, Larrick JW, Hu MC.
    J Immunother Cancer; 2021 Dec 20; 9(12):. PubMed ID: 34887262
    [Abstract] [Full Text] [Related]

  • 14. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V, Marcus D, van der Wiel AM, Lieuwes NG, Biemans R, Lieverse RI, Neri D, Theys J, Yaromina A, Dubois LJ, Lambin P.
    J Immunother Cancer; 2021 Mar 20; 9(3):. PubMed ID: 33688020
    [Abstract] [Full Text] [Related]

  • 15. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ.
    J Immunother Cancer; 2021 Apr 20; 9(4):. PubMed ID: 33849925
    [Abstract] [Full Text] [Related]

  • 16. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D, Jiang W, Zhu F, Mao X, Agrawal S.
    Int J Oncol; 2018 Sep 20; 53(3):1193-1203. PubMed ID: 29956749
    [Abstract] [Full Text] [Related]

  • 17. Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8+ T cells in cerebral malaria.
    Wang Y, Shen Y, Liang J, Wang S, Huang Y, Zhu Q, Zhang X, Yu K, Tong G, Yang C, Li Y, Wang J, Zhao Y.
    J Neuroinflammation; 2024 May 07; 21(1):119. PubMed ID: 38715061
    [Abstract] [Full Text] [Related]

  • 18. Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity.
    Wang CI, Chang YF, Sie ZL, Ho AS, Chang JS, Peng CL, Cheng CC.
    Cells; 2021 Sep 23; 10(10):. PubMed ID: 34685495
    [Abstract] [Full Text] [Related]

  • 19. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, Nemenoff RA.
    Cancer Immunol Res; 2017 Sep 23; 5(9):767-777. PubMed ID: 28819064
    [Abstract] [Full Text] [Related]

  • 20. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R, Liu C, Zheng S, Wang X, Feng X, Li H, Sun N, He J.
    Cancer Biol Med; 2020 Aug 15; 17(3):768-781. PubMed ID: 32944405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.